Stereoselective Metabolism of the 5-Lipoxygenase Inhibitor A-78773

Based on the knowledge that glucuronidation was a major route of metabolism of the N-hydroxyurea class of 5-lipoxygenase inhibitors, a simple in vitro glucuronidation assay was established using liver microsomes from various species, including man. Compounds that were potent inhibitors of 5-LO and s...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the New York Academy of Sciences 1994-11, Vol.744 (1), p.262-273
Main Authors: CARTER, GEORGE W., BELL, RANDY L., MARSH, KENNAN, LANNI, CARMINE, AWNI, WALID M., BOUSKA, JENNIFER, STEWART, ANDREW O., HANSEN, ROBERT, DUBÉ, LOUISE, BROOKS, DEE W.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3232-63777b0f3e526eff7222850ae6aee81ad01eb0cd5d7fbc4902977a447f373f6e3
cites cdi_FETCH-LOGICAL-c3232-63777b0f3e526eff7222850ae6aee81ad01eb0cd5d7fbc4902977a447f373f6e3
container_end_page 273
container_issue 1
container_start_page 262
container_title Annals of the New York Academy of Sciences
container_volume 744
creator CARTER, GEORGE W.
BELL, RANDY L.
MARSH, KENNAN
LANNI, CARMINE
AWNI, WALID M.
BOUSKA, JENNIFER
STEWART, ANDREW O.
HANSEN, ROBERT
DUBÉ, LOUISE
BROOKS, DEE W.
description Based on the knowledge that glucuronidation was a major route of metabolism of the N-hydroxyurea class of 5-lipoxygenase inhibitors, a simple in vitro glucuronidation assay was established using liver microsomes from various species, including man. Compounds that were potent inhibitors of 5-LO and showed a reduced metabolic liability in vitro were then characterized more extensively in experimental animals. This prudent usage of in vitro glucuronidation proved to be highly efficient and was indispensable in the identification of A-78773, a potent new long-acting 5-LO inhibitor. Further studies with liver microsomes revealed that glucuronidation of A-78773 was stereoselective and that the R(+) enantiomer was considerably more resistant to conjugation than the S(-) stereoisomer. Pharmacokinetic studies in experimental animals and humans confirmed the greater metabolic stability of the R(+) enantiomer. A single 400-mg oral dose of A-78773 inhibited ex vivo leukotriene biosynthesis for more than 24 hours. Since 78% of the drug plasma AUC following A-78773 administration was accounted for by the R(+) enantiomer, it is reasonable to assume that the majority of the leukotriene inhibition caused by the racemate is attributable to the R(+) enantiomer, A-79175, particularly at the later times. The equivalent 5-lipoxygenase inhibitory potency coupled with the superior pharmacokinetic profile of the R(+) enantiomer, A79175, compared to the S(-) enantiomer, A-79176, indicate that the development of this compound may be preferable to the racemate A-78773.
doi_str_mv 10.1111/j.1749-6632.1994.tb52744.x
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76944153</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76944153</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3232-63777b0f3e526eff7222850ae6aee81ad01eb0cd5d7fbc4902977a447f373f6e3</originalsourceid><addsrcrecordid>eNqVkE1v2kAQhldVK0JIf0IlK4fe7OyXd7y5VCQKhIgSKRC1Pa3WZjZZajDxmhT-fYxA3DuXObzvPCM9hFwymrB2rhYJA6ljpQRPmNYyafKUg5TJ9hPpnqLPpEspQJxpLs7IeQgLShnPJHRIBzKeZlJ3yc20wRqrgCUWjX_H6Cc2Nq9KH5ZR5aLmFaM0Hvt1td294MoGjEarV5_7pqqjfgwZgLggX5wtA3497h55HtzNbu_j8eNwdNsfx4XggsdKAEBOncCUK3QOOOdZSi0qi5gxO6cMc1rM0zm4vJCacg1gpQQnQDiFoke-H7jrunrbYGjM0ocCy9KusNoEA0pLyVLRFq8PxaKuQqjRmXXtl7beGUbNXqBZmL0ls7dk9gLNUaDZtsffjl82-RLnp9OjsTb_ccj_-RJ3_0E2kz_9KVe8JcQHgg8Nbk8EW_81CgSk5tdkaLKnwe-H2UybofgAN0SO-A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76944153</pqid></control><display><type>article</type><title>Stereoselective Metabolism of the 5-Lipoxygenase Inhibitor A-78773</title><source>Wiley Online Library All Backfiles</source><creator>CARTER, GEORGE W. ; BELL, RANDY L. ; MARSH, KENNAN ; LANNI, CARMINE ; AWNI, WALID M. ; BOUSKA, JENNIFER ; STEWART, ANDREW O. ; HANSEN, ROBERT ; DUBÉ, LOUISE ; BROOKS, DEE W.</creator><creatorcontrib>CARTER, GEORGE W. ; BELL, RANDY L. ; MARSH, KENNAN ; LANNI, CARMINE ; AWNI, WALID M. ; BOUSKA, JENNIFER ; STEWART, ANDREW O. ; HANSEN, ROBERT ; DUBÉ, LOUISE ; BROOKS, DEE W.</creatorcontrib><description>Based on the knowledge that glucuronidation was a major route of metabolism of the N-hydroxyurea class of 5-lipoxygenase inhibitors, a simple in vitro glucuronidation assay was established using liver microsomes from various species, including man. Compounds that were potent inhibitors of 5-LO and showed a reduced metabolic liability in vitro were then characterized more extensively in experimental animals. This prudent usage of in vitro glucuronidation proved to be highly efficient and was indispensable in the identification of A-78773, a potent new long-acting 5-LO inhibitor. Further studies with liver microsomes revealed that glucuronidation of A-78773 was stereoselective and that the R(+) enantiomer was considerably more resistant to conjugation than the S(-) stereoisomer. Pharmacokinetic studies in experimental animals and humans confirmed the greater metabolic stability of the R(+) enantiomer. A single 400-mg oral dose of A-78773 inhibited ex vivo leukotriene biosynthesis for more than 24 hours. Since 78% of the drug plasma AUC following A-78773 administration was accounted for by the R(+) enantiomer, it is reasonable to assume that the majority of the leukotriene inhibition caused by the racemate is attributable to the R(+) enantiomer, A-79175, particularly at the later times. The equivalent 5-lipoxygenase inhibitory potency coupled with the superior pharmacokinetic profile of the R(+) enantiomer, A79175, compared to the S(-) enantiomer, A-79176, indicate that the development of this compound may be preferable to the racemate A-78773.</description><identifier>ISSN: 0077-8923</identifier><identifier>EISSN: 1749-6632</identifier><identifier>DOI: 10.1111/j.1749-6632.1994.tb52744.x</identifier><identifier>PMID: 7825849</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Animals ; Humans ; Hydroxyurea - analogs &amp; derivatives ; Hydroxyurea - metabolism ; Leukotriene Antagonists ; Leukotrienes - biosynthesis ; Lipoxygenase Inhibitors - metabolism ; Microsomes, Liver - metabolism ; Neutrophils - metabolism ; Rats ; Stereoisomerism ; Tumor Cells, Cultured</subject><ispartof>Annals of the New York Academy of Sciences, 1994-11, Vol.744 (1), p.262-273</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3232-63777b0f3e526eff7222850ae6aee81ad01eb0cd5d7fbc4902977a447f373f6e3</citedby><cites>FETCH-LOGICAL-c3232-63777b0f3e526eff7222850ae6aee81ad01eb0cd5d7fbc4902977a447f373f6e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1749-6632.1994.tb52744.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1749-6632.1994.tb52744.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1410,27901,27902,46024,46448</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7825849$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CARTER, GEORGE W.</creatorcontrib><creatorcontrib>BELL, RANDY L.</creatorcontrib><creatorcontrib>MARSH, KENNAN</creatorcontrib><creatorcontrib>LANNI, CARMINE</creatorcontrib><creatorcontrib>AWNI, WALID M.</creatorcontrib><creatorcontrib>BOUSKA, JENNIFER</creatorcontrib><creatorcontrib>STEWART, ANDREW O.</creatorcontrib><creatorcontrib>HANSEN, ROBERT</creatorcontrib><creatorcontrib>DUBÉ, LOUISE</creatorcontrib><creatorcontrib>BROOKS, DEE W.</creatorcontrib><title>Stereoselective Metabolism of the 5-Lipoxygenase Inhibitor A-78773</title><title>Annals of the New York Academy of Sciences</title><addtitle>Ann N Y Acad Sci</addtitle><description>Based on the knowledge that glucuronidation was a major route of metabolism of the N-hydroxyurea class of 5-lipoxygenase inhibitors, a simple in vitro glucuronidation assay was established using liver microsomes from various species, including man. Compounds that were potent inhibitors of 5-LO and showed a reduced metabolic liability in vitro were then characterized more extensively in experimental animals. This prudent usage of in vitro glucuronidation proved to be highly efficient and was indispensable in the identification of A-78773, a potent new long-acting 5-LO inhibitor. Further studies with liver microsomes revealed that glucuronidation of A-78773 was stereoselective and that the R(+) enantiomer was considerably more resistant to conjugation than the S(-) stereoisomer. Pharmacokinetic studies in experimental animals and humans confirmed the greater metabolic stability of the R(+) enantiomer. A single 400-mg oral dose of A-78773 inhibited ex vivo leukotriene biosynthesis for more than 24 hours. Since 78% of the drug plasma AUC following A-78773 administration was accounted for by the R(+) enantiomer, it is reasonable to assume that the majority of the leukotriene inhibition caused by the racemate is attributable to the R(+) enantiomer, A-79175, particularly at the later times. The equivalent 5-lipoxygenase inhibitory potency coupled with the superior pharmacokinetic profile of the R(+) enantiomer, A79175, compared to the S(-) enantiomer, A-79176, indicate that the development of this compound may be preferable to the racemate A-78773.</description><subject>Animals</subject><subject>Humans</subject><subject>Hydroxyurea - analogs &amp; derivatives</subject><subject>Hydroxyurea - metabolism</subject><subject>Leukotriene Antagonists</subject><subject>Leukotrienes - biosynthesis</subject><subject>Lipoxygenase Inhibitors - metabolism</subject><subject>Microsomes, Liver - metabolism</subject><subject>Neutrophils - metabolism</subject><subject>Rats</subject><subject>Stereoisomerism</subject><subject>Tumor Cells, Cultured</subject><issn>0077-8923</issn><issn>1749-6632</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><recordid>eNqVkE1v2kAQhldVK0JIf0IlK4fe7OyXd7y5VCQKhIgSKRC1Pa3WZjZZajDxmhT-fYxA3DuXObzvPCM9hFwymrB2rhYJA6ljpQRPmNYyafKUg5TJ9hPpnqLPpEspQJxpLs7IeQgLShnPJHRIBzKeZlJ3yc20wRqrgCUWjX_H6Cc2Nq9KH5ZR5aLmFaM0Hvt1td294MoGjEarV5_7pqqjfgwZgLggX5wtA3497h55HtzNbu_j8eNwdNsfx4XggsdKAEBOncCUK3QOOOdZSi0qi5gxO6cMc1rM0zm4vJCacg1gpQQnQDiFoke-H7jrunrbYGjM0ocCy9KusNoEA0pLyVLRFq8PxaKuQqjRmXXtl7beGUbNXqBZmL0ls7dk9gLNUaDZtsffjl82-RLnp9OjsTb_ccj_-RJ3_0E2kz_9KVe8JcQHgg8Nbk8EW_81CgSk5tdkaLKnwe-H2UybofgAN0SO-A</recordid><startdate>199411</startdate><enddate>199411</enddate><creator>CARTER, GEORGE W.</creator><creator>BELL, RANDY L.</creator><creator>MARSH, KENNAN</creator><creator>LANNI, CARMINE</creator><creator>AWNI, WALID M.</creator><creator>BOUSKA, JENNIFER</creator><creator>STEWART, ANDREW O.</creator><creator>HANSEN, ROBERT</creator><creator>DUBÉ, LOUISE</creator><creator>BROOKS, DEE W.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199411</creationdate><title>Stereoselective Metabolism of the 5-Lipoxygenase Inhibitor A-78773</title><author>CARTER, GEORGE W. ; BELL, RANDY L. ; MARSH, KENNAN ; LANNI, CARMINE ; AWNI, WALID M. ; BOUSKA, JENNIFER ; STEWART, ANDREW O. ; HANSEN, ROBERT ; DUBÉ, LOUISE ; BROOKS, DEE W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3232-63777b0f3e526eff7222850ae6aee81ad01eb0cd5d7fbc4902977a447f373f6e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Animals</topic><topic>Humans</topic><topic>Hydroxyurea - analogs &amp; derivatives</topic><topic>Hydroxyurea - metabolism</topic><topic>Leukotriene Antagonists</topic><topic>Leukotrienes - biosynthesis</topic><topic>Lipoxygenase Inhibitors - metabolism</topic><topic>Microsomes, Liver - metabolism</topic><topic>Neutrophils - metabolism</topic><topic>Rats</topic><topic>Stereoisomerism</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CARTER, GEORGE W.</creatorcontrib><creatorcontrib>BELL, RANDY L.</creatorcontrib><creatorcontrib>MARSH, KENNAN</creatorcontrib><creatorcontrib>LANNI, CARMINE</creatorcontrib><creatorcontrib>AWNI, WALID M.</creatorcontrib><creatorcontrib>BOUSKA, JENNIFER</creatorcontrib><creatorcontrib>STEWART, ANDREW O.</creatorcontrib><creatorcontrib>HANSEN, ROBERT</creatorcontrib><creatorcontrib>DUBÉ, LOUISE</creatorcontrib><creatorcontrib>BROOKS, DEE W.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of the New York Academy of Sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CARTER, GEORGE W.</au><au>BELL, RANDY L.</au><au>MARSH, KENNAN</au><au>LANNI, CARMINE</au><au>AWNI, WALID M.</au><au>BOUSKA, JENNIFER</au><au>STEWART, ANDREW O.</au><au>HANSEN, ROBERT</au><au>DUBÉ, LOUISE</au><au>BROOKS, DEE W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stereoselective Metabolism of the 5-Lipoxygenase Inhibitor A-78773</atitle><jtitle>Annals of the New York Academy of Sciences</jtitle><addtitle>Ann N Y Acad Sci</addtitle><date>1994-11</date><risdate>1994</risdate><volume>744</volume><issue>1</issue><spage>262</spage><epage>273</epage><pages>262-273</pages><issn>0077-8923</issn><eissn>1749-6632</eissn><abstract>Based on the knowledge that glucuronidation was a major route of metabolism of the N-hydroxyurea class of 5-lipoxygenase inhibitors, a simple in vitro glucuronidation assay was established using liver microsomes from various species, including man. Compounds that were potent inhibitors of 5-LO and showed a reduced metabolic liability in vitro were then characterized more extensively in experimental animals. This prudent usage of in vitro glucuronidation proved to be highly efficient and was indispensable in the identification of A-78773, a potent new long-acting 5-LO inhibitor. Further studies with liver microsomes revealed that glucuronidation of A-78773 was stereoselective and that the R(+) enantiomer was considerably more resistant to conjugation than the S(-) stereoisomer. Pharmacokinetic studies in experimental animals and humans confirmed the greater metabolic stability of the R(+) enantiomer. A single 400-mg oral dose of A-78773 inhibited ex vivo leukotriene biosynthesis for more than 24 hours. Since 78% of the drug plasma AUC following A-78773 administration was accounted for by the R(+) enantiomer, it is reasonable to assume that the majority of the leukotriene inhibition caused by the racemate is attributable to the R(+) enantiomer, A-79175, particularly at the later times. The equivalent 5-lipoxygenase inhibitory potency coupled with the superior pharmacokinetic profile of the R(+) enantiomer, A79175, compared to the S(-) enantiomer, A-79176, indicate that the development of this compound may be preferable to the racemate A-78773.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>7825849</pmid><doi>10.1111/j.1749-6632.1994.tb52744.x</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0077-8923
ispartof Annals of the New York Academy of Sciences, 1994-11, Vol.744 (1), p.262-273
issn 0077-8923
1749-6632
language eng
recordid cdi_proquest_miscellaneous_76944153
source Wiley Online Library All Backfiles
subjects Animals
Humans
Hydroxyurea - analogs & derivatives
Hydroxyurea - metabolism
Leukotriene Antagonists
Leukotrienes - biosynthesis
Lipoxygenase Inhibitors - metabolism
Microsomes, Liver - metabolism
Neutrophils - metabolism
Rats
Stereoisomerism
Tumor Cells, Cultured
title Stereoselective Metabolism of the 5-Lipoxygenase Inhibitor A-78773
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T09%3A59%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stereoselective%20Metabolism%20of%20the%205-Lipoxygenase%20Inhibitor%20A-78773&rft.jtitle=Annals%20of%20the%20New%20York%20Academy%20of%20Sciences&rft.au=CARTER,%20GEORGE%20W.&rft.date=1994-11&rft.volume=744&rft.issue=1&rft.spage=262&rft.epage=273&rft.pages=262-273&rft.issn=0077-8923&rft.eissn=1749-6632&rft_id=info:doi/10.1111/j.1749-6632.1994.tb52744.x&rft_dat=%3Cproquest_cross%3E76944153%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3232-63777b0f3e526eff7222850ae6aee81ad01eb0cd5d7fbc4902977a447f373f6e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=76944153&rft_id=info:pmid/7825849&rfr_iscdi=true